Literature DB >> 35509637

Vitamin D Supplementation for 12 Months in Older Adults Alters Regulators of Bone Metabolism but Does Not Change Wnt Signaling Pathway Markers.

Marilena Christodoulou1, Terence J Aspray2, Isabelle Piec1, Christopher Washbourne1, Jonathan Cy Tang1, William D Fraser1, Inez Schoenmakers1.   

Abstract

Vitamin D status and supplementation regulates bone metabolism and may modulate Wnt signaling. We studied the response of hormonal regulators of bone metabolism, markers of Wnt signaling and bone turnover and bone mineral density (BMD) and bone mineral content (BMC) in a randomized vitamin D intervention trial (12,000 IU, 24,000 IU, 48,000 IU/mo for 1 year; men and women aged >70 years; n = 379; ISRCTN35648481). Associations with total and free 25(OH)D concentrations were analyzed by linear regression. Baseline vitamin D status was (mean ± SD) 25(OH)D: 40.0 ± 20.1 nmol/L. Supplementation dose-dependently increased total and free 25(OH)D concentrations and decreased plasma phosphate and parathyroid hormone (PTH) (all p < 0.05). The procollagen 1 intact N-terminal (PINP)/C-terminal telopeptide (CTX) ratio, C-terminal fibroblast growth factor-23 (cFGF23), and intact FGF23 (iFGF23) significantly increased with no between-group differences, whereas Klotho was unchanged. 1,25(OH)2D and PINP significantly increased in the 24 IU and 48,000 IU groups. Sclerostin (SOST), osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), BMD, BMC, and CTX remained unchanged. Subgroup analyses with baseline 25(OH)D <25 nmol/L (n = 94) provided similar results. Baseline total and free 25(OH)D concentrations were positively associated with 1,25(OH)2D, 24,25(OH)2D (p < 0.001), vitamin D binding protein (DBP) (p < 0.05), BMD, and BMC (p < 0.05). Associations with PTH (p <0.001), cFGF23 (p < 0.01), and BAP (p < 0.05) were negative. After supplementation, total and free 25(OH)D concentrations remained positively associated only with 24,25(OH)2D (p < 0.001) and DBP (p < 0.001) and negatively with estimated glomerular filtration rate (eGFR) (p < 0.01). PTH and SOST were significantly associated only with free 25(OH)D. There were no significant relationships with BMD and BMC after supplementation. The decrease in PTH and increase in PINP/CTX ratio suggest a protective effect of supplementation on bone metabolism, although no significant effect on BMD or pronounced changes in regulators of Wnt signaling were found. The increase in FGF23 warrants caution because of its negative association with skeletal and cardiovascular health. Associations of total and free 25(OH)D with biomarkers were similar and known positive associations between vitamin D status and BMD were confirmed. The change in associations after supplementation might suggest a threshold effect.
© 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE TURNOVER; FIBROBLAST GROWTH FACTOR‐23; PARATHYROID HORMONE; VITAMIN D; WNT PATHWAY

Year:  2022        PMID: 35509637      PMCID: PMC9059470          DOI: 10.1002/jbm4.10619

Source DB:  PubMed          Journal:  JBMR Plus        ISSN: 2473-4039


  68 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Vitamin D supplementation increases calcium absorption without a threshold effect.

Authors:  John F Aloia; Ruban Dhaliwal; Albert Shieh; Mageda Mikhail; Melissa Fazzari; Louis Ragolia; Steven A Abrams
Journal:  Am J Clin Nutr       Date:  2013-12-11       Impact factor: 7.045

Review 3.  Normal bone anatomy and physiology.

Authors:  Bart Clarke
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

4.  Significance of minimodeling in dialysis patients with adynamic bone disease.

Authors:  Yoshifumi Ubara; Tetsuo Tagami; Syohei Nakanishi; Naoki Sawa; Junichi Hoshino; Tatsuya Suwabe; Hideyuki Katori; Fumi Takemoto; Shigeko Hara; Kenmei Takaichi
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

5.  Vitamin D endocrine system and the intestine.

Authors:  Sylvia Christakos; Liesbet Lieben; Ritsuko Masuyama; Geert Carmeliet
Journal:  Bonekey Rep       Date:  2014-02-05

Review 6.  Why should we measure free 25(OH) vitamin D?

Authors:  Oleg Tsuprykov; Xin Chen; Carl-Friedrich Hocher; Roman Skoblo; Berthold Hocher
Journal:  J Steroid Biochem Mol Biol       Date:  2017-12-05       Impact factor: 4.292

Review 7.  Benefit-risk assessment of vitamin D supplementation.

Authors:  H A Bischoff-Ferrari; A Shao; B Dawson-Hughes; J Hathcock; E Giovannucci; W C Willett
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

8.  Effect of Vitamin D Treatment on Serum Sclerostin Level.

Authors:  F Acıbucu; H S Dokmetas; D O Acıbucu; F Kılıclı; M Aydemir; E Cakmak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2016-01-29       Impact factor: 2.949

9.  25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial.

Authors:  Helen M Macdonald; Ian R Reid; Gregory D Gamble; William D Fraser; Jonathan C Tang; Adrian D Wood
Journal:  J Bone Miner Res       Date:  2018-06-15       Impact factor: 6.741

Review 10.  FGF23 signalling and physiology.

Authors:  Bryan B Ho; Clemens Bergwitz
Journal:  J Mol Endocrinol       Date:  2021-02       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.